Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.

#What Is the Current and Projected Market Size of the Parkinson’s Disease Market Through 2034?#_x000D_

In the past few years, the market size of Parkinson’s disease has experienced a robust growth. The market, projected to rise from $3.34 billion in 2024 to $3.63 billion in 2025, boasts a compound annual growth rate (CAGR) of 8.5%. The substantial growth witnessed during the historic period can be credited to factors such as heightened research and development activities, increased government funding, the prevalence of bespoke treatment plans, the emergence of support networks for individuals with Parkinson’s disease, and the rising employment of cutting-edge rehabilitation therapies._x000D_

_x000D_

The market size for Parkinson’s disease is projected to experience substantial expansion in the coming years, reaching a value of $4.98 billion by 2029, with a Compound Annual Growth Rate (CAGR) of 8.2%. This projected growth for the forecast period is due to increased awareness of the symptoms of Parkinson’s disease, growing government initiatives, an increase in healthcare spending, an upsurge in clinical trials for Parkinson’s, and increased use of gene therapies. Key trends observed for this period comprise technological evolution, governmental support and funding, the use of artificial intelligence in diagnosing, innovative solutions, and customized medicine._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=21247&type=smp_x000D_

_x000D_

#Which Major Market Drivers Are Expected to Boost the Growth Potential of the Parkinson’s Disease Market?#_x000D_

The growth of the parkinson’s disease market is likely to be fuelled by the rising prevalence of neurodegenerative diseases. These diseases are a set of disorders that are characterized by a gradual degradation and loss of neurons’ functionality in the brain and nervous system. The rate of neurodegenerative diseases is escalating due to elements like an aging society, genetic susceptibility, environmental factors, enhanced diagnosis, an increase in chronic health problems, and shifts in lifestyle. Parkinson’s disease contributes to a better understanding of neurodegenerative diseases by revealing vital information about their underlying causes, possible treatment targets, and the inception of novel treatment methods. For example, as per the data of April 2022 from the European Brain Council, a non-profit organization based in Belgium, about 600 neurological diseases and almost 300 psychiatric conditions are affecting millions worldwide, including 65 million suffering from epilepsy. In Europe, dementia affects 10.5 million people, and predictions suggest this could surge to 18.7 million by 2050. Thus, the heightened prevalence of neurodegenerative diseases is driving the expansion of the parkinson’s disease market._x000D_

_x000D_

#Which Key Market Segments Comprise the Parkinson’s Disease Market and Drive Its Revenue Growth?#_x000D_

The parkinson’s disease market covered in this report is segmented –_x000D_

_x000D_

1) By Drug Class: Dopamine Agonists, Catechol-O-Methyltransferase Inhibitors, Monoamine Oxidase B Inhibitors, Anticholinergics, Carbidopa-Levodopa, Other Drug Classes_x000D_

2) By Route Of Administration: Oral, Injectable, Intestinal infusion, Subcutaneous, Other Route Of Administrations_x000D_

3) By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Online Pharmacies_x000D_

4) By Patient Care Setting: Clinics, Hospitals_x000D_

_x000D_

Subsegments:_x000D_

1) By Dopamine Agonists: Ergot Derivatives, Non-Ergot Derivatives_x000D_

2) By Catechol-O-Methyltransferase (COMT) Inhibitors: Entacapone, Tolcapone, Opicapone_x000D_

3) By Monoamine Oxidase B (MAO-B) Inhibitors: Selegiline, Rasagiline, Safinamide_x000D_

4) By Anticholinergics: Trihexyphenidyl, Benztropine, Procyclidine_x000D_

5) By Carbidopa-Levodopa: Immediate-Release Formulation, Extended-Release Formulation, Inhaled And Intestinal Gel Formulations_x000D_

6) By Other Drug Classes: Amantadine And Derivatives, Adenosine A2A Receptor Antagonists, Glutamate Antagonists_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=21247&type=smp_x000D_

_x000D_

#Which Areas Are Leading Regions in the Parkinson’s Disease Market Expansion Across the Globe?#_x000D_

North America was the largest region in the parkinson’s disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the parkinson’s disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#What Are the Key Market Trends in theParkinson’s Disease Market Over the Coming Years?#_x000D_

The principal players in the Parkinson’s disease market are honing their focus on cultivating cutting-edge solutions such as levodopa-based treatment strategies, designed to boost motor function and sustain consistent symptom management for patients suffering from advanced Parkinson’s disease. Levodopa-based treatment employs levodopa, a drug that transitions into dopamine within the brain, to uplift motor function and alleviate Parkinson’s symptoms. In October 2024, AbbVie Inc., a pioneering biopharmaceutical firm based out of the US, garnered approval from the US Food and Drug Administration (FDA) for VYALEV, a mixed therapy embodying levodopa and carbidopa specially crafted for treating Parkinson’s disease. The end-goal of its development is to elevate levodopa’s efficacy by holding off its deconstruction prior to reaching the brain, which in effect, escalates dopamine levels. This medication plays an instrumental role in controling Parkinson’s disease’s motor symptoms like tremors, stiffness, and slowed movements, thereby augmenting the patient’s capacity to perform daily activities. It is hailed as a vital therapeutic option for Parkinson’s patients encountering motor irregularities._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/parkinsons-disease-global-market-report_x000D_

_x000D_

#How Is the Parkinson’s Disease Market Conceptually Defined?#_x000D_

Parkinson’s disease is a progressive neurological disorder that affects movement due to the loss of dopamine-producing brain cells. It primarily causes tremors, muscle stiffness, slowed movement, and balance difficulties. Treatment often involves medications such as levodopa to alleviate symptoms, complemented by physical therapy and, in certain cases, surgical interventions such as deep brain stimulation._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21247_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 3156230293_x000D_

Asia +44 2071930708_x000D_

Europe +44 2071930708_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model